Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial.
Cannabis
Co-use
Marijuana
Pharmacotherapy
Polysubstance use
Tobacco cessation
Treatment
Varenicline
Journal
BMC psychology
ISSN: 2050-7283
Titre abrégé: BMC Psychol
Pays: England
ID NLM: 101627676
Informations de publication
Date de publication:
25 Jan 2023
25 Jan 2023
Historique:
received:
12
01
2023
accepted:
20
01
2023
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
Several evidence-based tobacco cessation treatment strategies exist, though significant barriers to cessation remain which must be addressed to improve abstinence rates for sub-populations of those smoking cigarettes. Cannabis co-use among those who use tobacco is common and appears to be increasing among adults in the United States (US). The literature evaluating the impact of cannabis use on tobacco cessation has been mixed and has several important limitations, which precludes development of treatment recommendations specific to individuals who use tobacco and co-use cannabis. To date, no prospective studies have evaluated the impact of cannabis use and severity on tobacco cessation or quantified cannabis use changes during tobacco treatment to assess for concurrent reductions, abstinence, or compensatory (i.e., increased) cannabis use. This study's aims are to: (1) evaluate tobacco cessation outcomes among participants who co-use cannabis compared to participants only using tobacco, (2) using daily diaries and biochemical verification, assess changes in cannabis use during tobacco treatment, and (3) assess for a dose-dependent impact of cannabis use on tobacco cessation. A multi-site, prospective, quasi-experimental 12-week tobacco treatment trial enrolling treatment-seeking adults (ages 18-40; N = 208) from three sites across South Carolina (US) who use tobacco daily and oversampling (2:1) those who co-use cannabis. Participants receive tobacco cessation pharmacotherapy (varenicline) paired with behavioral support, while cannabis use is not addressed as part of treatment. The primary outcome is 7-day point prevalence tobacco abstinence at the week 12 end of treatment visit, measured via biochemical verification and self-report. Secondary outcome measures include changes in cannabis use (via biochemical verification and self-report) during tobacco cessation treatment. Results from this trial have the potential to inform tobacco treatment among those co-using cannabis, which may require a tailored approach to address the role of cannabis in quitting tobacco. The trial is registered with ClinicalTrials.gov: NCT04228965. January 14th, 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Several evidence-based tobacco cessation treatment strategies exist, though significant barriers to cessation remain which must be addressed to improve abstinence rates for sub-populations of those smoking cigarettes. Cannabis co-use among those who use tobacco is common and appears to be increasing among adults in the United States (US). The literature evaluating the impact of cannabis use on tobacco cessation has been mixed and has several important limitations, which precludes development of treatment recommendations specific to individuals who use tobacco and co-use cannabis. To date, no prospective studies have evaluated the impact of cannabis use and severity on tobacco cessation or quantified cannabis use changes during tobacco treatment to assess for concurrent reductions, abstinence, or compensatory (i.e., increased) cannabis use. This study's aims are to: (1) evaluate tobacco cessation outcomes among participants who co-use cannabis compared to participants only using tobacco, (2) using daily diaries and biochemical verification, assess changes in cannabis use during tobacco treatment, and (3) assess for a dose-dependent impact of cannabis use on tobacco cessation.
METHOD
METHODS
A multi-site, prospective, quasi-experimental 12-week tobacco treatment trial enrolling treatment-seeking adults (ages 18-40; N = 208) from three sites across South Carolina (US) who use tobacco daily and oversampling (2:1) those who co-use cannabis. Participants receive tobacco cessation pharmacotherapy (varenicline) paired with behavioral support, while cannabis use is not addressed as part of treatment. The primary outcome is 7-day point prevalence tobacco abstinence at the week 12 end of treatment visit, measured via biochemical verification and self-report. Secondary outcome measures include changes in cannabis use (via biochemical verification and self-report) during tobacco cessation treatment.
DISCUSSION
CONCLUSIONS
Results from this trial have the potential to inform tobacco treatment among those co-using cannabis, which may require a tailored approach to address the role of cannabis in quitting tobacco.
TRIAL REGISTRATION
BACKGROUND
The trial is registered with ClinicalTrials.gov: NCT04228965. January 14th, 2020.
Identifiants
pubmed: 36698194
doi: 10.1186/s40359-023-01060-2
pii: 10.1186/s40359-023-01060-2
pmc: PMC9875760
doi:
Banques de données
ClinicalTrials.gov
['NCT04228965']
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Subventions
Organisme : NCI NIH HHS
ID : R37 CA237245
Pays : United States
Organisme : NIAAA NIH HHS
ID : T32 AA007474
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001450
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Addiction. 2021 Jul;116(7):1622-1630
pubmed: 33047862
Drug Alcohol Depend. 2022 Apr 1;233:109278
pubmed: 35151023
Addiction. 2020 Oct;115(10):1800-1814
pubmed: 32003088
Drug Alcohol Depend. 2011 Jan 15;113(2-3):249-51
pubmed: 20863627
Drug Alcohol Depend. 2016 Oct 01;167:228-32
pubmed: 27590743
Br J Addict. 1988 Apr;83(4):393-402
pubmed: 3395719
Am J Drug Alcohol Abuse. 2019;45(1):26-41
pubmed: 29513609
Drug Alcohol Depend. 2018 Apr 1;185:238-244
pubmed: 29471228
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109111
pubmed: 34655945
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1956-1964
pubmed: 34348959
Addiction. 2022 Jun;117(6):1768-1777
pubmed: 34985165
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Drug Alcohol Depend. 2018 Jan 1;182:1-7
pubmed: 29112827
Prev Med Rep. 2017 Mar 23;6:251-257
pubmed: 28392993
Nicotine Tob Res. 2020 Jul 16;22(8):1354-1363
pubmed: 31388679
Nicotine Tob Res. 2020 Jul 16;22(8):1374-1382
pubmed: 31612956
Curr Addict Rep. 2020 Dec;7(4):533-544
pubmed: 33777645
Psychol Addict Behav. 2014 Mar;28(1):154-62
pubmed: 23276315
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
Int J Drug Policy. 2020 Apr 16;79:102754
pubmed: 32305827
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Nicotine Tob Res. 2020 Jul 16;22(8):1383-1389
pubmed: 31616939
Nicotine Tob Res. 2022 Jan 1;24(1):125-129
pubmed: 34120176
Drug Alcohol Depend. 2017 Aug 1;177:249-257
pubmed: 28623823
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Nicotine Tob Res. 2022 Jan 1;24(1):53-59
pubmed: 34111281
JAMA Pediatr. 2019 Dec 1;173(12):1146-1153
pubmed: 31609433
Addict Behav. 2015 Oct;49:26-32
pubmed: 26036666
Drug Alcohol Depend. 2011 Dec 15;119(3):194-200
pubmed: 21724341
Lancet. 2016 Jun 18;387(10037):2507-20
pubmed: 27116918
Subst Use Misuse. 2018 Feb 23;53(3):501-507
pubmed: 28910232
Exp Clin Psychopharmacol. 2019 Jun;27(3):265-275
pubmed: 30556733
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Drug Alcohol Depend. 2021 Aug 1;225:108815
pubmed: 34171822
Nicotine Tob Res. 2022 Oct 17;24(10):1684-1688
pubmed: 35417562
JAMA. 2022 Apr 26;327(16):1566-1576
pubmed: 35471512
Contemp Clin Trials. 2014 Nov;39(2):211-23
pubmed: 25179587
Addict Behav. 2022 Dec;135:107434
pubmed: 35908323
JAMA Intern Med. 2018 May 1;178(5):622-631
pubmed: 29630702
Drug Alcohol Depend. 2016 Sep 01;166:6-12
pubmed: 27476751
Addiction. 2012 Aug;107(8):1404-17
pubmed: 22340422
JAMA. 2006 Jul 5;296(1):56-63
pubmed: 16820547
Addiction. 2018 Apr;113(4):719-728
pubmed: 29265574
JAMA. 2006 Jul 5;296(1):47-55
pubmed: 16820546
Clin Psychol Rev. 2012 Mar;32(2):105-21
pubmed: 22245559
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):397-405
pubmed: 35298455
Addiction. 2016 Feb;111(2):220-30
pubmed: 26392127
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681
Drug Alcohol Depend. 2016 Nov 01;168:119-122
pubmed: 27639129
Addict Behav. 2015 Dec;51:18-23
pubmed: 26186376
Subst Use Misuse. 2017 Sep 19;52(11):1449-1459
pubmed: 28467153
J Psychoactive Drugs. 2018 Jul-Aug;50(3):195-205
pubmed: 29199906
Am J Public Health. 2018 Jan;108(1):137-142
pubmed: 29161058
Stat Med. 2004 Oct 15;23(19):2937-60
pubmed: 15351954
Drug Alcohol Depend. 2011 Jul 1;116(1-3):142-50
pubmed: 21310551
Drug Alcohol Depend. 2022 Sep 1;238:109563
pubmed: 35870333